Medtronic美敦力品牌怎么样 申请店铺

创立于1949年美国，全球知名的医疗技术/服务和解决方案提供商，2015年收购柯惠医疗，起搏器行业享有较高声誉

1949年4月29日，美敦力由Earl E. Bakken和Palmer J. Hermundslie在美国明尼苏达州明尼阿波利斯市创建。在2014年4月结束的财务年度，美敦力全球营收超过170亿美元。2014年6月，美敦力宣布以429亿美元收购柯惠医疗，合并完成后的美敦力公司将成为年营收超过270亿美元、员工近9万名的全球较大医疗器械公司。

美敦力自1996年进入中国以来，业务飞速发展，提供包括心脏起搏器、Endeavor支架、胰岛素泵、脊柱植入物、大脑起搏器、心脏外科以及耳鼻喉器材在内的多种产品与疗法。除了在上海设有美敦力大中华区总部、心脏起搏器生产线和物流中心外，美敦力还在中国内地设有10个办事处，在台湾和香港亦设有分支机构，拥有1500多人的生产、管理与技术支持队伍，10多年来直接服务的患者已累计近百万。

2008年，美敦力与山东威高集团合资成立美敦力威高骨科有限公司，迈出了本土化的重要一步。2010年8月8日，美敦力与卫计委心血管病防治研究中心合作，成立了健康关爱中心，为众多慢性疾病患者及家属提供了与专家直接对话、探讨治疗方案的机会。2011年3月，美敦力大中华区新的总部大楼在上海张江高科技园区落成，标志着美敦力扎根中国的决心与信心。

2014年7月28日，美敦力和先健科技共同宣布了扩大双方的战略合作，为中国病患提供在中国本土生产的心脏起搏器。按照合作协议，先健科技将在其位于中国深圳的工厂建立心脏起搏器生产软硬件设施，开发包括心脏起搏器和导线在内的新产品组合。美敦力将为先健科技进入中国心脏起搏市场的计划提供特定的技术、培训和支持。

2014年8月4日，美敦力与成都市政府签署战略合作协议，并在成都高新区设立美敦力肾护理业务中心、投资建设新型、便携式肾透析设备生产线，产品适用于诊所和非医院环境。

10多年来，美敦力在中国的累计捐赠与资助超过3000万元。例如，美敦力曾资助世界健康基金会在中国开展了为期三年的健康心脏教育项目，培训了1800多名中国基层医生；2007年，美敦力主题公益活动“梦想的翅膀”为30名糖尿病青少年患者捐赠了胰岛素泵，帮助他们回归正常生活；汶川地震后，美敦力累计向灾区捐赠440万元的现金及医疗器材。

研发方面，美敦力每年将收入的10%用于新技术和新产品的开发。美敦力还根据自己认准的行业方向，深入认识疾病状态，研究不同技术组合及治疗措施，逐步实现从“医疗器材”到“疾病管理”的跨越。

2015年1月27日，美敦力公司（NYSE：MDT）宣布已经成功完成对柯惠医疗公司（NYSE：COV）的并购。根据并购协议条款，美敦力公司（Medtronic Inc.）和柯惠医疗公司（Covidien plc）合并为美敦力有限公司（Medtronic plc.）。美敦力有限公司的股票将在美国当地时间（2015年1月27日）在纽约证券交易所开始交易。

Founded in the United States in 1949, it is a world-renowned provider of medical technology / services and solutions. In 2015, it acquired cowei medical. Pacemaker industry enjoys a high reputation. On April 29, 1949, Medtronic was founded by earle.bakken and Palmer j.hermundslie in Minneapolis, Minnesota. In the financial year ended April 2014, Medtronic's global revenue exceeded $17 billion. In June 2014, Medtronic announced the acquisition of Kohei medical with us $42.9 billion. After the merger, Medtronic will become a large global medical device company with an annual revenue of more than US $27 billion and nearly 90000 employees. Since its entry into China in 1996, Medtronic's business has developed rapidly, providing a variety of products and therapies including cardiac pacemakers, endeavor stents, insulin pumps, spinal implants, brain pacemakers, cardiac surgery and ear, nose and throat equipment. In addition to its headquarters in Greater China, pacemaker production line and logistics center in Shanghai, Medtronic also has 10 offices in mainland China, branches in Taiwan and Hong Kong, and more than 1500 production, management and technical support teams. In the past 10 years, it has directly served nearly one million patients. In 2008, Medtronic and Shandong Weigao group jointly established Medtronic Weigao orthopedics Co., Ltd., which took an important step in localization. On August 8, 2010, Medtronic, in cooperation with the Research Center for cardiovascular disease prevention and control of the health and Family Planning Commission, established a health care center, providing many patients with chronic diseases and their families with the opportunity to have a direct dialogue with experts and explore treatment options. In March 2011, the new headquarters building of Medtronic Greater China was completed in Zhangjiang High Tech Park, Shanghai, marking the determination and confidence of Medtronic to take root in China. On July 28, 2014, Medtronic and Xianjian technology jointly announced to expand their strategic cooperation to provide Chinese patients with pacemakers made in China. According to the cooperation agreement, SK technology will establish hardware and software facilities for pacemaker production in its factory in Shenzhen, China, and develop a new product portfolio including pacemakers and wires. Medtronic will provide specific technology, training and support for cenjian's plans to enter the Chinese cardiac pacing market. On August 4, 2014, Medtronic signed a strategic cooperation agreement with Chengdu municipal government, established Medtronic renal care business center in Chengdu high tech Zone, invested in the construction of new and portable renal dialysis equipment production line, and the products are suitable for clinic and non hospital environment. Over the past 10 years, Medtronic has donated and subsidized more than 30 million yuan in China. For example, Medtronic has funded the World Health Foundation to carry out a three-year healthy heart education project in China and trained more than 1800 Chinese grassroots doctors; in 2007, Medtronic's theme public welfare activity "wings of dreams" donated insulin pumps to 30 young diabetics to help them return to normal life; after the Wenchuan earthquake, Medtronic donated 4.4 million yuan to the disaster area in total Yuan in cash and medical equipment. In terms of R & D, Medtronic devotes 10% of its revenue to the development of new technologies and products every year. Medtronic also has a deep understanding of the disease status, research on different technology combinations and treatment measures according to its own recognized industry direction, and gradually realize the leap from "medical equipment" to "disease management". On January 27, 2015, Medtronic (NYSE: MDT) announced that it had successfully completed the merger and acquisition of cov. Under the terms of the merger agreement, Medtronic Inc. and covidienplc merged into Medtronic PLC. Medtronic's shares will begin trading on the New York Stock Exchange on January 27, 2015, local time in the United States.

本文链接： https://brand.waitui.com/291ed52af.html 联系电话：400-820-0869,021-20325888